drugset / Trial / NCT00177047
Autologous Transplant for Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
Timeline
- Start
- 2004-04-20
- Primary completion
- 2020-08-01
- Completion
- 2020-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 200 mg/m2 | Intravenous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | 4 mg/m2 | — |
| Background | Granulocyte colony-stimulating factor | Protein / enzyme biologic | 5 ug/kg | Intravenous |